Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
TG1-M5218 | Mouse | Mouse TGF-Beta 1 / TGFB1 Protein, Tag Free | ![]() |
![]() ![]() |
![]() ![]() |
TG1-H8217 | Human | Biotinylated Human TGF-Beta 1 / TGFB1 Protein, Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
TG1-H4212 | Human | ActiveMax® Human TGF-Beta 1 / TGFB1 Protein, Tag Free | ![]() |
![]() ![]() |
![]() ![]() |
Biotinylated Human TGF-Beta 1, Avitag™ (Cat. No. TG1-H8217) inhibits the IL-4-dependent proliferation of TF-1 cells. The ED50 for this effect is 3.30-8.33 ng/mL (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Pirfenidone | F-647; AMR-69; GP-101; S-7701; S-770108; RO-0220912 | Approved | Intermune | 艾思瑞, Deskar, Etuary, Esbriet, Pirespa, Aisuryui | United States | Idiopathic Pulmonary Fibrosis | s:13:"Genentech Inc"; | 2008-10-16 | Radiation Pneumonitis; Renal Insufficiency; Dermatomyositis; Idiopathic Pulmonary Fibrosis; Scleroderma, Systemic; Pulmonary Fibrosis; Lung Diseases, Interstitial; Diabetic Nephropathies; Alveolitis, Extrinsic Allergic; Pneumoconiosis | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Nicousamide | XLF-III-43 | Phase 2 Clinical | Institue Of Materia Medica Chinese Academy Of Medical Science | Hypertensive nephropathy; Diabetic Nephropathies | Details |
盐酸美氟尼酮 | Phase 1 Clinical | Guangzhou Nanxin Pharmaceutical Co Ltd, Central South University | Diabetic Nephropathies | Details | |
DW-1029M | DW-1029M | Phase 2 Clinical | Dong Wha Pharmaceuticals | Diabetic Nephropathies | Details |
Disitertide | P-144; NAFB-001; Peptide-144 | Phase 2 Clinical | Digna Biotech, University Of Navarra | Fibrosis; Scleroderma, Systemic | Details |
Fluorofenidone | AKF-PD | Phase 1 Clinical | Dierepharma HK Ltd, Hainan Haiyao Co Ltd, Central South University | Liver Cirrhosis; Renal fibrosis | Details |
YL-13027 | YL-13027 | Phase 1 Clinical | Shanghai Yingli Pharmaceutical Co Ltd | Solid tumours | Details |
Vactosertib | EW-7197; NOV-1301; TEW-7197 | Phase 2 Clinical | Medpacto | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Myelodysplastic Syndromes; Carcinoma, Transitional Cell; Urologic Neoplasms; Colorectal Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
Bintrafusp alfa | M-7824; GSK-4045154; MSB-0011359C | Phase 3 Clinical | Merck Serono | Biliary Tract Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Cholangiocarcinoma; Gallbladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
STP-705 | STP-705; STP-705L; STP-705LU; STP-705LV | Phase 2 Clinical | Suzhou Shengnuo Biological Medicine Technology Co Ltd, Sirnaomics | Liver Neoplasms; Bowen's Disease; Carcinoma, Basal Cell; Cholangiocarcinoma; Carcinoma, Squamous Cell; Cicatrix, Hypertrophic; Carcinoma, Hepatocellular | Details |
Yinfenidone Hydrochloride | HEC-585; HEC-00000585 | Phase 2 Clinical | Hec Pharm Co Ltd | Idiopathic Pulmonary Fibrosis | Details |
This web search service is supported by Google Inc.